Strategic partnerships MAbSilico has existing collaboration history with Ose Immunotherapeutics and a recent HDX-MS epitope mapping service launch through a partnership with Rapid Novor, indicating openness to co-development and service-based engagements with biotech and pharma companies.

AI-driven discovery The company specializes in AI-based antibody design and in silico developability assessments, offering rapid computational candidates ready for biological validation, which appeals to organizations seeking faster time-to-result and reduced upfront R&D risk.

Expand Europe With a footprint in Tours, France and past office expansion in Europe, there is potential to pursue European pharmaceutical and biotech clients, CROs, and academic collaborations seeking EU-based AI chemistry and biotech services.

Diversified offerings In addition to design, MAbSilico leverages NLP-enabled competitive landscape analysis and integrated epitope, affinity, off-target risk, and developability assessments, enabling bundled services for antibody discovery programs.

Financials & scale Revenue is in the $0–1M range with 11–50 employees, suggesting a nimble, growth-oriented partner suitable for pilot projects, sponsored research, or early-access arrangements with larger pharma entities seeking innovative AI-backed discovery tools.